Paper40485603
Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment.
Ma J and 9 others. Adv Sci (Weinh), 2025. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment. Papers, record 40485603. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40485603
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Proto-Oncogene Proteins p21(ras) | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Animals | |
| Mutation | |
| Microbiota |
Source PubMed
Grants11
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82173342 | National Natural Science Foundation of China | PubMed | ||
| 82203015 | National Natural Science Foundation of China | PubMed | ||
| 82373275 | National Natural Science Foundation of China | PubMed | ||
| 82403920 | National Natural Science Foundation of China | PubMed | ||
| 2024JJ6662 | Natural Science Foundation of Hunan Province | PubMed | ||
| 2025JJ20077 | Natural Science Foundation of Hunan Province | PubMed | ||
| 2024RC3042 | Science and Technology Innovation Program of Hunan Province | PubMed | ||
| 2023Q01 | Youth Science Foundation of Xiangya Hospital | PubMed | ||
| GZC20242044 | Postdoctoral Fellowship Program of the CPSF | PubMed | ||
| 2024M753679 | China Postdoctoral Science Foundation | PubMed | ||
| kq2403008 | Nature Science Foundation of Changsha | PubMed |
Source PubMed
References158
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26037647 | Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. | Mol Cancer Res | 2015 | https://conductscience.org/library/papers/26037647 | PubMed |
| 2 | 23852309 | Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23852309 | PubMed |
| 3 | 32467386 | The human tumor microbiome is composed of tumor type-specific intracellular bacteria. | Science | 2020 | https://conductscience.org/library/papers/32467386 | PubMed |
| 4 | 35219699 | Mucin 5AC-Mediated CD44/ITGB1 Clustering Mobilizes Adipose-Derived Mesenchymal Stem Cells to Modulate Pancreatic Cancer Stromal Heterogeneity. | Gastroenterology | 2022 | https://conductscience.org/library/papers/35219699 | PubMed |
| 5 | 34644529 | Spatially confined sub-tumor microenvironments in pancreatic cancer. | Cell | 2021 | https://conductscience.org/library/papers/34644529 | PubMed |
| 6 | 35836817 | Integrated multi-omics characterization of KRAS mutant colorectal cancer. | Theranostics | 2022 | https://conductscience.org/library/papers/35836817 | PubMed |
| 7 | 31578522 | The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. | Nature | 2019 | https://conductscience.org/library/papers/31578522 | PubMed |
| 8 | 34244683 | Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. | Nat Rev Cancer | 2021 | https://conductscience.org/library/papers/34244683 | PubMed |
| 9 | 21646616 | Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21646616 | PubMed |
| 10 | 31827278 | Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis. | Nature | 2019 | https://conductscience.org/library/papers/31827278 | PubMed |
| 11 | 33870211 | The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. | Nat Cancer | 2021 | https://conductscience.org/library/papers/33870211 | PubMed |
| 12 | 30721664 | Early Detection of Pancreatic Cancer: Opportunities and Challenges. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30721664 | PubMed |
| 13 | 32814111 | In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. | Gastroenterology | 2020 | https://conductscience.org/library/papers/32814111 | PubMed |
| 14 | 38402201 | Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15. | Nat Commun | 2024 | https://conductscience.org/library/papers/38402201 | PubMed |
| 15 | 31827279 | KRAS4A directly regulates hexokinase 1. | Nature | 2019 | https://conductscience.org/library/papers/31827279 | PubMed |
| 16 | 30738221 | Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). | J Thorac Oncol | 2019 | https://conductscience.org/library/papers/30738221 | PubMed |
| 17 | 36229606 | Metabolic communication in the tumour-immune microenvironment. | Nat Cell Biol | 2022 | https://conductscience.org/library/papers/36229606 | PubMed |
| 18 | 37344586 | Injury prevents Ras mutant cell expansion in mosaic skin. | Nature | 2023 | https://conductscience.org/library/papers/37344586 | PubMed |
| 19 | 24464042 | Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. | Nat Neurosci | 2014 | https://conductscience.org/library/papers/24464042 | PubMed |
| 20 | 37775182 | Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer. | Genes Dev | 2023 | https://conductscience.org/library/papers/37775182 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42817222 | Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer. | Cancer Rep (Hoboken) | 2026 | https://conductscience.org/library/papers/42817222 | PubMed |
| 42729994 | Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them. | Cancer Drug Resist | 2026 | https://conductscience.org/library/papers/42729994 | PubMed |
| 42490421 | KRASG12D inhibition reprograms the tumor-induced immunosuppressive environment and enhances NK cell-mediated antitumor immunity. | Sci Adv | 2026 | https://conductscience.org/library/papers/42490421 | PubMed |
| 42465857 | Microbiota in pancreatic cancer: Roles in tumor initiation and progression (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/42465857 | PubMed |
| 42218726 | Current advances in immunotherapy for KRAS-Mutant pancreatic cancer. | Clin Exp Med | 2026 | https://conductscience.org/library/papers/42218726 | PubMed |
| 42164352 | DARS2 serves as an independent prognostic factor and participates in multiple biological processes in bladder urothelial carcinoma. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/42164352 | PubMed |
| 42122957 | Pancreatic Cancer in the Holobiont and Therapeutic Targets: A Review. | J Clin Med | 2026 | https://conductscience.org/library/papers/42122957 | PubMed |
| 41924551 | Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/41924551 | PubMed |
| 41836721 | From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41836721 | PubMed |
| 41827015 | Systematic and precise interventions for KRAS-mutant cancers. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/41827015 | PubMed |
| 40936169 | Novel Evolutionarily Conserved Oncogene COA4 is Driven by KRAS Mutant and Promotes Cancer Metastasis Through Dual Mitochondrial Metabolism-Dependent and -Independent Mechanisms. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40936169 | PubMed |
| 40725204 | RETRACTED: The Impact of Fusobacterium nucleatum and the Genotypic Biomarker KRAS on Colorectal Cancer Pathogenesis. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40725204 | PubMed |
| 40485603 | Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40485603 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40485603
GET https://conductscience.org/api/papers/v1/40485603/references?page=2